[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567541":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":30,"locations":39,"responsibleParty":59,"collaborators":62,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":21,"enrollmentInfo":76,"targetDuration":21,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":42,"whyStopped":21,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-pregnant women","EXPERIMENTAL","Non-pregnant women will either receive 600 mcg misoprostol (3 tablets) or identical placebo 3 (tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).",[13,14],"Drug: Placebo","Drug: Misoprostol",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Placebo","Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Misoprostol","Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).",[9],[27],{"name":28,"affiliation":5,"role":29},"Warner K Huh, MD","PRINCIPAL_INVESTIGATOR",[31,35],{"name":28,"role":32,"phone":33,"phoneExt":21,"email":34},"CONTACT","2059341555","whuh@uabmc.edu",{"name":36,"role":32,"phone":37,"phoneExt":21,"email":38},"Simon M Manga, PhD","2059345612","smanga@uab.edu",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital Yaoundé","RECRUITING","Yaoundé","Center Region","2034","Cameroon","CM",{"type":49,"coordinates":50},"Point",[51,52],11.51667,3.86667,{"lat":52,"lon":51},[55,56,57,58],{"name":36,"role":32,"phone":37,"phoneExt":21,"email":38},{"name":28,"role":32,"phone":33,"phoneExt":21,"email":34},{"name":28,"role":29,"phone":21,"phoneExt":21,"email":21},{"name":36,"role":29,"phone":21,"phoneExt":21,"email":21},{"type":29,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Warner Huh","Professor",[63],{"name":64,"class":6},"Cameroon Baptist Convention Health","100567541","use-misoprostol-to-optimize-prevention-of-cervical-cancer-100567541",false,"NCT06669533","Use Misoprostol to Optimize Prevention of Cervical Cancer","Misoprostol to Optimizing Prevention of Cancer of the Cervix: A Double-Blind Randomized Controlled Trial","MISOPCx","Inclusion Criteria:\n\n* Diagnosis of Type 3 TZ confirmed on exam prior to randomization\n* Age 25 years or older\n\nExclusion Criteria:\n\n* With Type 1 or 2 TZ prior to randomization\n* Currently pregnant\n* History of hysterectomy\n* Any cancerous lesions\n* Active cervicitis",true,"FEMALE","25 Years",{"count":77,"type":78},420,"ESTIMATED","INTERVENTIONAL",[81],"NA","This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.",[84],"Cervical Cancers",[86],"cervical cancers","2025-09-29",{"date":89,"type":90},"2025-10-01","ACTUAL",{"date":92,"type":90},"2025-02-25",{"date":94,"type":78},"2027-11-04",{"name":5,"class":6},1]